(Q56998406)

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Attitudes toward male fertility control: results of a multinational survey on four continents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Would women trust their partners to use a male pill?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Recent advances in hormonal male contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Advances in male hormonal contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Contraceptive efficacy of testosterone-induced azoospermia in normal men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Contraceptive efficacy of a depot progestin and androgen combination in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

A Clinical Trial of 7α-Methyl-19-Nortestosterone Implants for Possible Use as a Long-Acting Contraceptive for Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Low dose of cyproterone acetate and testosterone enanthate for contraception in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

The low gonadotropin-independent constitutive production of testicular testosterone is sufficient to maintain spermatogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Twenty-One Day Administration of Dienogest Reversibly Suppresses Gonadotropins and Testosterone in Normal Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Combination of subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel for male hormonal contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389

A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.389